GREENFIELD, Ind. — Elanco Animal Health Inc. reports its financial results for the third quarter of 2024, provided guidance for the fourth quarter of 2024, and tightened guidance for the full year 2024.
“Elanco's expanding portfolio supported our fifth consecutive quarter of underlying organic constant currency revenue growth in the third quarter, and we continue to expect 3 percent organic constant currency growth for the full year,” Jeff Simmons, Elanco president and CEO, said. “It's exciting to see our Innovation, Portfolio and Productivity strategy come to life with new products driving growth, led by Experior®, Adtab and. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
